



# Asthmatic airway remodeling: long overlooked but too important to ignore

Amanda L. Tatler<sup>^</sup>

Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK

Correspondence to: Amanda L. Tatler. Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, UK.

Email: amanda.tatler@nottingham.ac.uk.

Comment on: Huang Y, Qiu C. Research advances in airway remodeling in asthma: a narrative review. *Ann Transl Med* 2022;10:1023.

**Keywords:** Asthma; airway remodelling; fibrosis; airway smooth muscle (ASM)

Submitted Nov 17, 2022. Accepted for publication Dec 05, 2022. Published online Dec 7, 2022.

doi: 10.21037/atm-22-5733

View this article at: <https://dx.doi.org/10.21037/atm-22-5733>

Structural changes within the asthmatic airway were first described 100 years ago by Huber and Koessler in cases of fatal asthma (1). The term “airway remodelling” emerged later as a collective term to describe a variety of airway structural changes including increased airway smooth muscle (ASM) mass, subepithelial fibrosis, epithelial metaplasia and increased vascularisation. Together these changes lead to a thickened and stiffer airway wall over time, which drives fixed airflow obstruction in asthmatic patients with important implications for symptoms and management (2,3). Airway remodelling and fixed airflow obstruction are associated with increased asthma severity and accelerated decline in lung function in asthma patients (3,4). It is clear, therefore, that attempts to halt or reduce airway remodelling could have a hugely beneficial impact on patients living with asthma, particularly those living with the severest forms of the disease.

Despite fixed airflow obstruction (also known as irreversibility of airflow obstruction) being described as far back as 1977 (5) by Professor Turner-Warwick, it has remained an understudied and often overlooked pathological feature of asthma, as evidenced by the fact that we still have no effective treatments that halt or reverse airway remodelling. In this issue of *Annals of Translational Medicine* Huang and Qiu provide an in depth narrative review

of recent advances in asthmatic airway remodelling (6), an article that is timely if we are to push forward our understanding of the mechanisms driving this critical but often ignored pathological feature of asthma. Only through better understanding will we collectively be able to develop novel therapies that halt or reverse asthmatic airway remodelling.

The underlying pathological mechanisms driving airway remodeling in asthma are complex and incompletely understood but as Huang and Qiu highlight, the fact that airway remodeling develops despite the use of anti-inflammatory drugs suggests that it occurs in conjunction with airway inflammation rather than being driven by it (6). This is supported by the observations that airway remodeling has been observed in preschool wheezers, which do not correlate with airway inflammation and predate an asthma diagnosis (2,7,8). In 2011, Grainge *et al.* demonstrated a potential role for bronchoconstriction as a driver of airway remodeling (9), which has since been supported by numerous studies (2,10,11). A direct biomechanical link between airway contraction and the development of airway remodeling could help to explain why worse airway remodeling is associated with more severe, difficult to treat and/or poorly controlled forms of asthma. Conversely, however, it is possible that the presence

<sup>^</sup> ORCID: 0000-0002-4644-4614.

of airway remodeling creates an asthma phenotype that is inherently difficult to treat. Huang and Qiu make the case that airway remodeling contributes to glucocorticoid resistance in asthma, which is a major component of difficult to treat asthma (6). Whether airway remodeling is the result of or a driver of severe, difficult to treat asthma is still largely unclear and an area that warrants further study.

## Acknowledgments

*Funding:* None.

## Footnote

*Provenance and Peer Review:* This article was commissioned by the editorial office, *Annals of Translational Medicine*. The article did not undergo external peer review.

*Conflicts of Interest:* The author has completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5733/coif>). ALT reports funding from Medical Research Council, Cystic Fibrosis Foundation and Medical Research Foundation; consulting fees from Pliant Therapeutics, Accession Therapeutics and Australian Rare Lung Disease Short course. She is treasurer of British Association for Lung Research and programming committee of RCMB and American Thoracic Society.

*Ethical Statement:* The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the

formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Huber HL, Koessler KK. The pathology of bronchial asthma. *Arch Intern Med* 1922;30:689-760.
2. Joseph C, Tatler AL. Pathobiology of Airway Remodeling in Asthma: The Emerging Role of Integrins. *J Asthma Allergy* 2022;15:595-610.
3. Krings JG, Goss CW, Lew D, et al. Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3. *J Allergy Clin Immunol* 2021;148:752-62.
4. Kozlik P, Zuk J, Bartyzel S, et al. The relationship of airway structural changes to blood and bronchoalveolar lavage biomarkers, and lung function abnormalities in asthma. *Clin Exp Allergy* 2020;50:15-28.
5. Turner-Warwick M. On observing patterns of airflow obstruction in chronic asthma. *Br J Dis Chest* 1977;71:73-86.
6. Huang Y, Qiu C. Research advances in airway remodeling in asthma: a narrative review. *Ann Transl Med* 2022;10:1023.
7. Lezmi G, Gosset P, Deschildre A, et al. Airway Remodeling in Preschool Children with Severe Recurrent Wheeze. *Am J Respir Crit Care Med* 2015;192:164-71.
8. Saglani S, Payne DN, Zhu J, et al. Early detection of airway wall remodeling and eosinophilic inflammation in preschool wheezers. *Am J Respir Crit Care Med* 2007;176:858-64.
9. Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. *N Engl J Med* 2011;364:2006-15.
10. Hill MR, Philp CJ, Billington CK, et al. A theoretical model of inflammation- and mechanotransduction-driven asthmatic airway remodelling. *Biomech Model Mechanobiol* 2018;17:1451-70.
11. Ramis J, Middlewick R, Pappalardo F, et al. Lysyl oxidase like 2 is increased in asthma and contributes to asthmatic airway remodelling. *Eur Respir J* 2022;60:2004361.

**Cite this article as:** Tatler AL. Asthmatic airway remodeling: long overlooked but too important to ignore. *Ann Transl Med* 2023;11(2):29. doi: 10.21037/atm-22-5733